Fate Therapeutics Inc

2 de set. de 2026, 19:46 UTC

Fate Therapeutics has begun the phase 2 RECLAIM-LN trial for FT819 in lupus nephritis, with the first patient dosed in an outpatient setting. Shares are higher.

1 de set. de 2026, 23:16 UTC

Fate Therapeutics Inc shares are lower in after-market hours, reflecting broader market trends amid rising oil prices and inflation concerns.

31 de ago. de 2026, 21:01 UTC

Fate Therapeutics Inc shares are lower in after-market hours, continuing a downward trend amid broader market sentiment influenced by hawkish Fed remarks.

26 de ago. de 2026, 19:46 UTC

Fate Therapeutics shares are higher Wednesday, despite a pullback from earlier gains. No specific news was identified to explain the price movement.

24 de ago. de 2026, 19:46 UTC

Fate Therapeutics Inc is trading higher amid broader market dynamics influenced by rising oil prices and geopolitical tensions, though no specific news was identified.

22 de ago. de 2026, 00:02 UTC

Fate Therapeutics Inc shares are higher in after-market trading, reflecting broader market gains following recent pressures from rising crude oil prices and bond yields.

20 de ago. de 2026, 20:06 UTC

Fate Therapeutics Inc is declining today, mirroring a broader market drop. The stock remains below its 20-day moving average and near its one-month low.

19 de ago. de 2026, 19:26 UTC

Fate Therapeutics Inc shares are higher, supported by a significant rise in the ARK Genomic Revolution ETF during Wednesday's session.

14 de ago. de 2026, 19:26 UTC

Fate Therapeutics has begun its Phase 2 RECLAIM-LN trial for FT819, targeting lupus nephritis. Shares are higher during Friday's session.

13 de ago. de 2026, 23:36 UTC

Fate Therapeutics shares are higher in after-market hours, reflecting a recovery from earlier declines amid broader market optimism regarding the Federal Reserve's interest rate policy.

12 de ago. de 2026, 21:02 UTC

Fate Therapeutics Inc. is gaining in after-market trading, rebounding from three consecutive sessions of declines. The price remains above the 20-day moving average.

7 de ago. de 2026, 20:03 UTC

Fate Therapeutics shares are higher, reaching a session high amid rising U.S. Treasury yields and a weakening U.S. Dollar Index. No specific news identified.

6 de ago. de 2026, 19:26 UTC

Fate Therapeutics Inc shares are lower today, reflecting broader market trends and a decline in the Russell 2000 Index amid ongoing inflation concerns.

5 de ago. de 2026, 19:56 UTC

Fate Therapeutics shares are higher amid positive market sentiment and falling oil prices, despite some volatility during Wednesday's trading session.

4 de ago. de 2026, 20:07 UTC

Fate Therapeutics is gaining as it announces employee inducement awards, including stock options at $2.45 per share. Shares rebounded after an earlier pullback.

3 de ago. de 2026, 23:01 UTC

Fate Therapeutics Inc. shares are lower in after-market trading, despite stronger growth in the manufacturing sector and recent employee inducement awards.

29 de jul. de 2026, 19:19 UTC

Fate Therapeutics is trading higher amid positive market momentum ahead of the Federal Reserve's monetary policy announcement, despite lingering inflation concerns.

28 de jul. de 2026, 16:06 UTC

Fate Therapeutics shares are lower amid broader market weakness and investor caution ahead of key earnings reports and the Federal Reserve's interest rate decision.

27 de jul. de 2026, 21:02 UTC

Fate Therapeutics shares are higher in after-market hours, despite no specific news. Broader market sentiment is improving with rising European equity indices.

24 de jul. de 2026, 19:07 UTC

Fate Therapeutics shares are lower, pressured by a notable decline in first-quarter results and broader market sentiment. They remain below the 20-day moving average.

23 de jul. de 2026, 21:11 UTC

Fate Therapeutics Inc. shares are higher in after-market hours, reflecting broader market gains. No specific company news has been identified to explain this increase.

22 de jul. de 2026, 23:46 UTC

Fate Therapeutics Inc shares are higher in after-market trading, reflecting a modest gain since Wednesday's close, despite no specific news identified.

20 de jul. de 2026, 18:26 UTC

Fate Therapeutics Inc. shares are effectively unchanged as trading remains flat. The stock has seen strong performance over the past month, nearing its recent highs.